Form 4: Sensei Biotherapeutics Director Acquires Stock Options

James Peyer, a director of Sensei Biotherapeutics, acquired stock options for 19,000 shares at an exercise price of $0.709 on June 11, 2024.

Summary

• James Peyer, a director of Sensei Biotherapeutics, acquired stock options to purchase 19,000 shares of common stock.
• The transaction occurred on June 11, 2024.
• The exercise price of the stock options is $0.709 per share.
• The options vest in 12 equal monthly installments, becoming fully vested by June 11, 2025, contingent upon continuous service with Sensei Biotherapeutics.
• The options are also fully vested on the date of the Company's next annual stockholder meeting, subject to continuous service with the Issuer through such vesting date.
• These options are held by Cambrian Biopharma Inc., where Mr. Peyer serves as CEO.
• Mr. Peyer disclaims beneficial ownership of these options, as Cambrian's Board of Directors' approval is required in certain instances.

Sentiment

Score: 6

Explanation: The document is a neutral regulatory filing. The acquisition of stock options could be viewed slightly positively as it indicates the director's confidence in the company, but it's a routine transaction.

Positives

• The acquisition of stock options by a director could be seen as a positive sign, indicating confidence in the company's future performance.

Management Comments

• Mr. Peyer disclaims beneficial ownership of such options.

Industry Context

This filing is a routine disclosure related to insider transactions, common in the biopharmaceutical industry where stock options are frequently used as part of executive compensation packages.

Comparison to Industry Standards

• Stock option grants are a common form of compensation for directors and executives in the biotechnology industry.
• Companies like Amgen, Gilead Sciences, and Biogen also utilize stock options as part of their compensation packages to align the interests of management with those of shareholders.
• The vesting schedule of 12 months is fairly standard.

Stakeholder Impact

• The acquisition of stock options by a director may have a minor positive impact on shareholder sentiment.

Key Dates

Keywords

stock options, Form 4, Sensei Biotherapeutics, SNSE, director, James Peyer, Cambrian Biopharma, beneficial ownership, vesting